Breaking News Instant updates and real-time market news.

AAPL

Apple

$352.30 /

+8.36 (+2.43%)

07:24
06/11/20
06/11
07:24
06/11/20
07:24

Apple price target raised to $390 from $340 at BofA

BofA analyst Wamsi Mohan raised the firm's price target on Apple to $390 from $340 and keeps a Buy rating on the shares. Mohan has raised his multiple on the stock, noting that the multiple typically expands heading into a product cycle and that the 5G cycle is set to start with the next set of iPhones. He also believes Apple's stability of cash flows demands a higher multiple and notes that other large cap tech companies carry more risks of regulation.

AAPL Apple
$352.30 /

+8.36 (+2.43%)

06/11/20 HSBC
HSBC upgrades Apple to Hold, boosts target to $295 from $225
06/10/20 HSBC
Apple upgraded to Hold from Reduce at HSBC
06/10/20 Deutsche Bank
Apple price target raised to $350 from $320 at Deutsche Bank
06/08/20 KeyBanc
iPhone sell-through improves modestly as stores begin to reopen, says KeyBanc

TODAY'S FREE FLY STORIES

General news
Asian Market Update: » 02:00
07/10/20
07/10
02:00
07/10/20
02:00

Asian Market Update:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Upgrade
Sleep Number upgraded to Overweight from Neutral at Piper Sandler » 21:42
07/09/20
07/09
21:42
07/09/20
21:42
SNBR

Sleep Number

$46.77 /

+0.27 (+0.58%)

Piper Sandler analyst…

Piper Sandler analyst Peter Keith upgraded Sleep Number to Overweight from Neutral.

ShowHide Related Items >><<
SNBR Sleep Number
$46.77 /

+0.27 (+0.58%)

SNBR Sleep Number
$46.77 /

+0.27 (+0.58%)

03/25/20 Raymond James
Sleep Number downgraded to Market Perform on weak traffic at Raymond James
03/25/20 Raymond James
Sleep Number downgraded to Market Perform from Outperform at Raymond James
02/20/20 Raymond James
Sleep Number price target raised to $62 from $54 at Raymond James
02/20/20 Wedbush
Sleep Number price target raised to $59 from $45 at Wedbush
SNBR Sleep Number
$46.77 /

+0.27 (+0.58%)

SNBR Sleep Number
$46.77 /

+0.27 (+0.58%)

Downgrade
Redfin downgraded to Sector Perform from Outperform at RBC Capital » 21:31
07/09/20
07/09
21:31
07/09/20
21:31
RDFN

Redfin

$40.12 /

-1.44 (-3.46%)

RBC Capital analyst Mark…

RBC Capital analyst Mark Mahaney downgraded Redfin to Sector Perform from Outperform and maintained a $41 price target. The analyst views valuation as "reasonably" balanced and said fundamentals remain "intact."

ShowHide Related Items >><<
RDFN Redfin
$40.12 /

-1.44 (-3.46%)

RDFN Redfin
$40.12 /

-1.44 (-3.46%)

06/25/20 SunTrust
Redfin price target raised to $48 from $30 at SunTrust
06/11/20 DA Davidson
Redfin price target raised to $42 from $27 at DA Davidson
06/10/20 BTIG
Redfin initiated with a Buy at BTIG
06/04/20 SunTrust
Zillow price target raised to $68 from $55 at SunTrust
RDFN Redfin
$40.12 /

-1.44 (-3.46%)

RDFN Redfin
$40.12 /

-1.44 (-3.46%)

RDFN Redfin
$40.12 /

-1.44 (-3.46%)

Conference/Events
UBS property analyst to hold an analyst/industry conference call » 21:00
07/09/20
07/09
21:00
07/09/20
21:00

Property Analyst Lam…

Property Analyst Lam discusses whether China shopping malls will survive or thrive in a post COVID-19 world on an Analyst/Industry conference call to be held on July 9 at 9:30 pm.

Recommendations
Piper Sandler remains 'apprehensive' on Integra LifeSciences after Q2 revenue » 20:24
07/09/20
07/09
20:24
07/09/20
20:24
IART

Integra LifeSciences

$46.22 /

-0.555 (-1.19%)

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien keeps his Neutral rating and $53 price target on Integra LifeSciences after the company pre-announced Q2 revenue above consensus driven by the return of elective procedure as many states lifted Shelter in Place guidance. While the sequential improvement is encouraging though, the company is not comfortably quantifying the impact of the pandemic into the 2nd half of the year as the situation remains "fairly ambiguous", the analyst tells investors in a research note.

ShowHide Related Items >><<
IART Integra LifeSciences
$46.22 /

-0.555 (-1.19%)

IART Integra LifeSciences
$46.22 /

-0.555 (-1.19%)

05/27/20
Fly Intel: Top five analyst initiations
05/27/20 Citi
Integra LifeSciences initiated with a Neutral at Citi
05/21/20 Piper Sandler
Early diligence on new Tactile Systems CEO very positive, says Piper Sandler
05/08/20 JMP Securities
Integra LifeSciences price target lowered to $65 from $75 at JMP Securities
IART Integra LifeSciences
$46.22 /

-0.555 (-1.19%)

IART Integra LifeSciences
$46.22 /

-0.555 (-1.19%)

Hot Stocks
Flowers Foods pauses production at Savannah, GA bakery due to COVID-19 » 19:57
07/09/20
07/09
19:57
07/09/20
19:57
FLO

Flowers Foods

$21.68 /

-0.26 (-1.19%)

Flowers Foods announced…

Flowers Foods announced that it has temporarily stopped production at its bakery in Savannah, Georgia due to an increase in confirmed COVID-19 cases within its production staff and in the number of those self-quarantining. The bakery's shipping, engineering, sanitation, and office teams continue to work at the facility, but 115 production employees have been furloughed. Flowers will pay furloughed production employees and ask those employees to shelter-in-place until the bakery resumes production.

ShowHide Related Items >><<
FLO Flowers Foods
$21.68 /

-0.26 (-1.19%)

FLO Flowers Foods
$21.68 /

-0.26 (-1.19%)

05/15/20 SunTrust
Flowers Foods price target raised to $25 from $20 at SunTrust
01/22/20 Jefferies
Flowers Foods initiated with a Hold at Jefferies
01/22/20 Jefferies
Flowers Foods initiated with a Hold at Jefferies
12/11/19 Deutsche Bank
Flowers Foods resumed with a Hold at Deutsche Bank
FLO Flowers Foods
$21.68 /

-0.26 (-1.19%)

FLO Flowers Foods
$21.68 /

-0.26 (-1.19%)

Hot Stocks
Bionano Genomics launches new DNA kit for tumor analysis » 19:31
07/09/20
07/09
19:31
07/09/20
19:31
BNGO

Bionano Genomics

$0.49 /

+0.0144 (+3.04%)

Bionano Genomics…

Bionano Genomics announced that it has launched the new Bionano Prep SP Tissue and Tumor Kit, a DNA isolation kit developed expressly for analysis of tumors and tissue with Bionano's Saphyr system. The kit has been designed to simplify isolation of Ultra High Molecular Weight DNA from a variety of solid tumors and tissue types. The new kit and protocol for the Saphyr system make the analysis of genomic rearrangements in cancer and model genomes that are of interest in pharmaceutical development simpler and more feasible than currently available methods.

ShowHide Related Items >><<
BNGO Bionano Genomics
$0.49 /

+0.0144 (+3.04%)

BNGO Bionano Genomics
$0.49 /

+0.0144 (+3.04%)

04/08/20 Oppenheimer
Oppenheimer bullish on Bionano Genomics, initiates with an Outperform
04/08/20 Oppenheimer
Bionano Genomics initiated with an Outperform at Oppenheimer
BNGO Bionano Genomics
$0.49 /

+0.0144 (+3.04%)

Syndicate
Poseida Therapeutics 14M share IPO priced at $16.00 » 19:26
07/09/20
07/09
19:26
07/09/20
19:26
PSTX

Poseida Therapeutics

$0.00 /

+ (+0.00%)

The deal size was…

The deal size was increased from 10M shares to 14M shares and priced at high end of $14.00-$16.00 target range. BofA, Piper Sandler and William Blair are acting as joint book running managers for the offering.

ShowHide Related Items >><<
  • 10
    Jul
Syndicate
Centogene 3.5M share Secondary priced at $14.00 » 19:22
07/09/20
07/09
19:22
07/09/20
19:22
CNTG

Centogene

$17.06 /

-2.1 (-10.96%)

The deal priced below the…

The deal priced below the last closing price of $17.07. Credit Suisse and SVB Leerink are acting as joint book running managers for the offering.

ShowHide Related Items >><<
CNTG Centogene
$17.06 /

-2.1 (-10.96%)

CNTG Centogene
$17.06 /

-2.1 (-10.96%)

04/24/20 BTIG
Centogene price target raised to $23 from $18 at BTIG
04/24/20 Evercore ISI
Centogene downgraded to In Line from Outperform at Evercore ISI
12/03/19 Baird
Centogene initiated with an Outperform at Baird
12/02/19 BTIG
Centogene initiated with a Buy at BTIG
  • 10
    Jul
  • 07
    Nov
CNTG Centogene
$17.06 /

-2.1 (-10.96%)

Initiation
Occidental Petroleum initiated with a Buy at Goldman Sachs » 19:14
07/09/20
07/09
19:14
07/09/20
19:14
OXY

Occidental Petroleum

$16.28 /

-1 (-5.79%)

Goldman Sachs initiated…

Goldman Sachs initiated coverage of Occidental Petroleum with a Buy rating.

ShowHide Related Items >><<
OXY Occidental Petroleum
$16.28 /

-1 (-5.79%)

OXY Occidental Petroleum
$16.28 /

-1 (-5.79%)

06/23/20 Barclays
Occidental Petroleum price target raised to $21 from $15 at Barclays
06/19/20 SunTrust
Occidental Petroleum upgraded to Buy from Hold at SunTrust
06/19/20 Mizuho
Occidental Petroleum price target raised to $18 from $13 at Mizuho
06/19/20 SunTrust
Occidental Petroleum upgraded to Buy from Hold at SunTrust
OXY Occidental Petroleum
$16.28 /

-1 (-5.79%)

OXY Occidental Petroleum
$16.28 /

-1 (-5.79%)

OXY Occidental Petroleum
$16.28 /

-1 (-5.79%)

OXY Occidental Petroleum
$16.28 /

-1 (-5.79%)

Downgrade
GEA Group downgraded to Neutral from Buy at Goldman Sachs » 19:06
07/09/20
07/09
19:06
07/09/20
19:06
GEAGY

GEA Group

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Daniela Costa downgraded GEA Group to Neutral from Buy with an unchanged EUR 27 price target. The company's end markets have been resilient during the Coronavirus with some cyclical recovery in Dairy Processing orders also observed, the analyst tells investors in a research note. Costa notes however that GEA's positive factors are "more than priced in" following a "strong" share price performance, with the stock valuation at a 10-year peak on a 12-month forward expected earnings basis.

ShowHide Related Items >><<
GEAGY GEA Group
$0.00 /

+ (+0.00%)

06/01/20 Barclays
GEA Group price target raised to EUR 31 from EUR 30 at Barclays
05/28/20 Barclays
GEA Group price target raised to EUR 30 from EUR 29 at Barclays
05/28/20 Credit Suisse
GEA Group price target raised to EUR 22 from EUR 21 at Credit Suisse
05/27/20 Deutsche Bank
GEA Group price target raised to EUR 19 from EUR 15 at Deutsche Bank
On The Fly
Fly Intel: After-Hours Movers » 19:02
07/09/20
07/09
19:02
07/09/20
19:02
SLP

Simulations Plus

$63.55 /

+1.57 (+2.53%)

, PSMT

PriceSmart

$60.38 /

+0.895 (+1.50%)

, MATX

Matson

$27.46 /

-0.69 (-2.45%)

, ZIOP

Ziopharm

$3.24 /

+0.04 (+1.25%)

, IART

Integra LifeSciences

$46.22 /

-0.555 (-1.19%)

, WDFC

WD-40

$200.59 /

-2.48 (-1.22%)

, FC

Franklin Covey

$19.18 /

-1.125 (-5.54%)

, KERN

Akerna

$7.25 /

-0.21 (-2.82%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

WDFC WD-40
$200.59 /

-2.48 (-1.22%)

SLP Simulations Plus
$63.55 /

+1.57 (+2.53%)

PSMT PriceSmart
$60.38 /

+0.895 (+1.50%)

MATX Matson
$27.46 /

-0.69 (-2.45%)

KERN Akerna
$7.25 /

-0.21 (-2.82%)

IART Integra LifeSciences
$46.22 /

-0.555 (-1.19%)

FC Franklin Covey
$19.18 /

-1.125 (-5.54%)

SLP Simulations Plus
$63.55 /

+1.57 (+2.53%)

06/08/20 Craig-Hallum
Simulations Plus price target raised to $56 from $40 at Craig-Hallum
01/06/20 Craig-Hallum
Simulations Plus initiated with a Buy at Craig-Hallum
PSMT PriceSmart
$60.38 /

+0.895 (+1.50%)

05/08/20 Scotiabank
Scotiabank downgrades PriceSmart amid COVID-19 restrictions
05/08/20 Scotiabank
PriceSmart downgraded to Sector Perform from Outperform at Scotiabank
09/23/19 Kansas City Capital
PriceSmart downgraded to Perform from Outperform at Kansas City Capital
07/18/19
Fly Intel: Top five analyst upgrades
MATX Matson
$27.46 /

-0.69 (-2.45%)

04/06/20 Stephens
Matson downgraded to Equal Weight from Overweight at Stephens
02/27/20 Stifel
Matson upgraded to Buy from Hold at Stifel
ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

06/19/20 Jefferies
Ziopharm initiated with a Buy at Jefferies
05/11/20 H.C. Wainwright
Ziopharm price target lowered to $5.50 from $6.50 at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst initiations
03/04/20 Cantor Fitzgerald
Ziopharm initiated with Overweight, $6 price target at Cantor Fitzgerald
IART Integra LifeSciences
$46.22 /

-0.555 (-1.19%)

05/27/20
Fly Intel: Top five analyst initiations
05/27/20 Citi
Integra LifeSciences initiated with a Neutral at Citi
05/21/20 Piper Sandler
Early diligence on new Tactile Systems CEO very positive, says Piper Sandler
05/08/20 JMP Securities
Integra LifeSciences price target lowered to $65 from $75 at JMP Securities
WDFC WD-40
$200.59 /

-2.48 (-1.22%)

03/27/20 DA Davidson
WD-40 upgraded to Buy from Neutral at DA Davidson
03/27/20 DA Davidson
WD-40 upgraded to Buy from Neutral at DA Davidson
01/07/20 DA Davidson
WD-40 downgraded to Neutral from Buy at DA Davidson
01/07/20 DA Davidson
WD-40 downgraded to Neutral from Buy at DA Davidson
FC Franklin Covey
$19.18 /

-1.125 (-5.54%)

04/03/20 Roth Capital
Franklin Covey price target lowered to $28 from $51 at Roth Capital
03/30/20 B. Riley FBR
Franklin Covey price target lowered to $32 from $45 at B. Riley FBR
01/30/20
Franklin Covey management to meet with Roth Capital
KERN Akerna
$7.25 /

-0.21 (-2.82%)

ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

WDFC WD-40
$200.59 /

-2.48 (-1.22%)

SLP Simulations Plus
$63.55 /

+1.57 (+2.53%)

PSMT PriceSmart
$60.38 /

+0.895 (+1.50%)

MATX Matson
$27.46 /

-0.69 (-2.45%)

KERN Akerna
$7.25 /

-0.21 (-2.82%)

IART Integra LifeSciences
$46.22 /

-0.555 (-1.19%)

FC Franklin Covey
$19.18 /

-1.125 (-5.54%)

  • 05
    Feb
WDFC WD-40
$200.59 /

-2.48 (-1.22%)

WDFC WD-40
$200.59 /

-2.48 (-1.22%)

PSMT PriceSmart
$60.38 /

+0.895 (+1.50%)

KERN Akerna
$7.25 /

-0.21 (-2.82%)

ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

WDFC WD-40
$200.59 /

-2.48 (-1.22%)

SLP Simulations Plus
$63.55 /

+1.57 (+2.53%)

PSMT PriceSmart
$60.38 /

+0.895 (+1.50%)

KERN Akerna
$7.25 /

-0.21 (-2.82%)

FC Franklin Covey
$19.18 /

-1.125 (-5.54%)

Earnings
Simulations Plus reports Q3 EPS 16c, two estimates 9c » 18:58
07/09/20
07/09
18:58
07/09/20
18:58
SLP

Simulations Plus

$63.55 /

+1.57 (+2.53%)

Reports Q3 revenue…

Reports Q3 revenue $12.3M, two estimates $11.21M. Shawn O'Connor, chief executive officer of Simulations Plus, said: "Keeping with historical seasonality trends, the third quarter was again a strong quarter with revenue increasing 24% year-over-year to $12.3 million, demonstrating the significant progress we have made to accelerate growth. A solid base of recurring revenue and a large backlog of project-based service business have minimized the impact from current economic conditions resulting from the effects of the COVID-19 pandemic. While certain new customer software license and service projects were delayed in recent months, we continue to believe opportunities have been delayed, but not lost. Our backlog remains healthy, and we are encouraged by the pickup of new software license closures and consulting contracts at the end of the quarter. We expect double-digit, year-over-year revenue growth in the fiscal fourth quarter, despite the impact of seasonality on a sequential basis. The integration of Lixoft is going well and initial feedback from the marketplace has been positive as customers acknowledge the strengthening of our offerings with the Monolix Suite."

ShowHide Related Items >><<
SLP Simulations Plus
$63.55 /

+1.57 (+2.53%)

SLP Simulations Plus
$63.55 /

+1.57 (+2.53%)

06/08/20 Craig-Hallum
Simulations Plus price target raised to $56 from $40 at Craig-Hallum
01/06/20 Craig-Hallum
Simulations Plus initiated with a Buy at Craig-Hallum
SLP Simulations Plus
$63.55 /

+1.57 (+2.53%)

SLP Simulations Plus
$63.55 /

+1.57 (+2.53%)

Hot Stocks
Lancet publishes data on MacroGenics' Margetuximab in gastric cancer » 18:47
07/09/20
07/09
18:47
07/09/20
18:47
MGNX

MacroGenics

$30.66 /

-0.86 (-2.73%)

MacroGenics announced…

MacroGenics announced that Lancet Oncology has published results from a Phase 2 study of margetuximab plus pembrolizumab as a chemotherapy-free regimen for patients with advanced HER2-positive gastroesophageal adenocarcinoma who have previously been treated with chemotherapy and trastuzumab. The Phase 2 study enrolled patients with gastric cancer or gastroesophageal junction cancer whose tumors were IHC3-positive or IHC2-positive/FISH-positive at diagnosis. Enrollment was regardless of PD-L1 expression status, which was subsequently determined from available archived tumor tissue. Tolerability of margetuximab and pembrolizumab was acceptable in patients treated in this study. Grade 3 or higher treatment-related adverse events were reported in 20% of patients, with anemia and infusion-related reactions being the most common. No treatment-related deaths were reported. Patients who had received margetuximab at the recommended Phase 2 dose of 15 mg/kg every three weeks were evaluable for response. In this overall population, the objective response rate was 18%, including complete responses. Median progression-free survival was 2.7 months and median overall survival was 12.5 months.

ShowHide Related Items >><<
MGNX MacroGenics
$30.66 /

-0.86 (-2.73%)

MGNX MacroGenics
$30.66 /

-0.86 (-2.73%)

06/02/20 Citi
MacroGenics price target raised to $25 from $15 at Citi
06/01/20 Guggenheim
Guggenheim upgrades MacroGenics to Buy on pipeline prospects
06/01/20 Guggenheim
MacroGenics upgraded to Buy from Neutral at Guggenheim
05/29/20 Stifel
MacroGenics price target raised to $36 from $21 at Stifel
MGNX MacroGenics
$30.66 /

-0.86 (-2.73%)

MGNX MacroGenics
$30.66 /

-0.86 (-2.73%)

Hot Stocks
SPDR Gold Shares holdings fall to 1,200.82MT from 1202.57MT » 18:43
07/09/20
07/09
18:43
07/09/20
18:43
GLD

SPDR Gold Shares

$169.59 /

-0.41 (-0.24%)

This is the first decline…

This is the first decline in holdings since June 4th.

ShowHide Related Items >><<
GLD SPDR Gold Shares
$169.59 /

-0.41 (-0.24%)

GLD SPDR Gold Shares
$169.59 /

-0.41 (-0.24%)

GLD SPDR Gold Shares
$169.59 /

-0.41 (-0.24%)

GLD SPDR Gold Shares
$169.59 /

-0.41 (-0.24%)

Initiation
Autoliv initiated with a Buy at Goldman Sachs » 18:40
07/09/20
07/09
18:40
07/09/20
18:40
ALV

Autoliv

$63.32 /

-0.9 (-1.40%)

Goldman Sachs analyst…

Goldman Sachs analyst Gungun Verma initiated coverage of Autoliv with a Buy rating and a price target of $81. The company is a high-quality, defensive supplier that can significantly outgrow auto supplier peers through the cycle, the analyst tells investors in a research note. Verma adds that Autoliv is capable of expanding its EBIT margins to 12% by 2024, which would be above the global peer average of 7% expected over the next 5 years, and also notes that the stock offers a best-in-class cash profile within the supplier group.

ShowHide Related Items >><<
ALV Autoliv
$63.32 /

-0.9 (-1.40%)

ALV Autoliv
$63.32 /

-0.9 (-1.40%)

06/19/20 JPMorgan
Autoliv price target raised to $63 from $55 at JPMorgan
06/11/20 Evercore ISI
Autoliv upgraded to In Line from Underperform at Evercore ISI
05/28/20 Wolfe Research
Autoliv downgraded to Peer Perform from Outperform at Wolfe Research
05/19/20 UBS
Autoliv price target raised to $54 from $43 at UBS
ALV Autoliv
$63.32 /

-0.9 (-1.40%)

ALV Autoliv
$63.32 /

-0.9 (-1.40%)

Hot Stocks
Allergan says FDA approves expanded BOTOX label for spasticity treatment » 18:33
07/09/20
07/09
18:33
07/09/20
18:33
ABBV

AbbVie

$97.93 /

-1.35 (-1.36%)

Allergan, an AbbVie…

Allergan, an AbbVie company, announced that the U.S. Food and Drug Administration approved a supplemental Biologics License Application that supports expanded use of BOTOX for the treatment of spasticity in pediatric patients 2 years of age and older, including those with lower limb spasticity caused by cerebral palsy. This label expansion is based on Allergan and another manufacturer selectively waiving orphan exclusivity marketing rights each company held for the use of their respective neurotoxins in the treatment of pediatric patients with spasticity caused by cerebral palsy. BOTOX was first approved in June 2019 for the treatment of pediatric patients with upper limb spasticity and in October 2019 for the treatment of pediatric patients with lower limb spasticity, excluding spasticity caused by cerebral palsy. BOTOX has not been shown to improve upper extremity functional abilities, or range of motion at a joint affected by a fixed contracture.

ShowHide Related Items >><<
ABBV AbbVie
$97.93 /

-1.35 (-1.36%)

ABBV AbbVie
$97.93 /

-1.35 (-1.36%)

07/07/20 SunTrust
Evolus price target lowered to $6 from $12 at SunTrust
07/06/20 Piper Sandler
Biohaven launch of Nurtec 'continues to impress,' says Piper Sandler
06/29/20 Mizuho
AbbVie price target raised to $110 from $101 at Mizuho
06/26/20 Raymond James
Adverum Biotechnologies downgradedat Raymond James on abicipar CRL
ABBV AbbVie
$97.93 /

-1.35 (-1.36%)

ABBV AbbVie
$97.93 /

-1.35 (-1.36%)

ABBV AbbVie
$97.93 /

-1.35 (-1.36%)

ABBV AbbVie
$97.93 /

-1.35 (-1.36%)

Periodicals
Amazon to create at least $100M in stock awards to keep Zoox staff, Reuters says » 18:18
07/09/20
07/09
18:18
07/09/20
18:18
AMZN

Amazon.com

$3,184.49 /

+102.47 (+3.32%)

Amazon intends to create…

Amazon intends to create at least $100M in stock awards to retain the 900-plus staff members of Zoox, the self-driving car startup it offered to acquire last month, and can walk away from the deal if large numbers of the staff turn down job offers from Amazon, Reuters' Stephen Nellis and Jane Lanhee Lee report. The tech giant will pay $1.3B in cash for the deal, which the two sides hope to finalize by September, the authors note, citing deal documents. Reference Link

ShowHide Related Items >><<
AMZN Amazon.com
$3,184.49 /

+102.47 (+3.32%)

AMZN Amazon.com
$3,184.49 /

+102.47 (+3.32%)

07/09/20 Wedbush
Pinterest price target raised to $31 from $26 at Wedbush
07/09/20 Credit Suisse
Consumer survey highlights good initial interest in Walmart+, says Credit Suisse
07/08/20 Morgan Stanley
Walmart membership plan seems geared at protecting grocery, says Morgan Stanley
07/08/20 Oppenheimer
Walmart moving in on Amazon turf with new subscription service, says Oppenheimer
AMZN Amazon.com
$3,184.49 /

+102.47 (+3.32%)

AMZN Amazon.com
$3,184.49 /

+102.47 (+3.32%)

AMZN Amazon.com
$3,184.49 /

+102.47 (+3.32%)

AMZN Amazon.com
$3,184.49 /

+102.47 (+3.32%)

AMZN Amazon.com
$3,184.49 /

+102.47 (+3.32%)

Hot Stocks
Caesars to reopen Bally's Las Vegas on July 23rd » 18:00
07/09/20
07/09
18:00
07/09/20
18:00
CZR

Caesars

$12.28 /

+0.15 (+1.24%)

Caesars announced plans…

Caesars announced plans to resume operations at Bally's Las Vegas on Thursday, July 23 at 10 a.m. Pacific Time, following successful reopenings of Caesars Palace Las Vegas, Flamingo Las Vegas, Harrah's Las Vegas and Paris Las Vegas. As previously announced, the company has also reopened the gaming floor and other amenities at The LINQ Hotel + Experience, as well as The LINQ Promenade, High Roller Observation Wheel, FLY LINQ and Eiffel Tower Viewing Deck.

ShowHide Related Items >><<
CZR Caesars
$12.28 /

+0.15 (+1.24%)

CZR Caesars
$12.28 /

+0.15 (+1.24%)

07/08/20 Jefferies
Eldorado Resorts price target raised to $51 from $38 at Jefferies
06/29/20 Stifel
Stifel boosts Eldorado Resorts target to $60, sees 'triple-digit stock' soon
06/04/20 Deutsche Bank
Caesars price target raised to $12 from $11 at Deutsche Bank
06/02/20 Nomura Instinet
Eldorado Resorts price target raised to $34 from $12.50 at Nomura Instinet
CZR Caesars
$12.28 /

+0.15 (+1.24%)

CZR Caesars
$12.28 /

+0.15 (+1.24%)

CZR Caesars
$12.28 /

+0.15 (+1.24%)

CZR Caesars
$12.28 /

+0.15 (+1.24%)

Hot Stocks
Talos Energy receives notice from SENER to unitize Zama Field » 17:50
07/09/20
07/09
17:50
07/09/20
17:50
TALO

Talos Energy

$7.95 /

-0.5 (-5.92%)

Talos Energy announced…

Talos Energy announced that the company received a notice from Mexico's Ministry of Energy, or SENER, instructing the partners of Block 7 and Petroleos Mexicanos, or Pemex, to unitize the Zama field. Talos is the operator of Block 7 in a partnership with Wintershall Dea and Premier Oil. The Zama field extends from Block 7 into the neighboring block to the east, which is operated by Pemex; therefore, to maximize the value of the reserves the constitution of a formal unit is required prior to the final investment decision, or FID and field development. Under Mexican regulation, the four parties now have up to 120 business days to deliver a Unitization and Unit Operating Agreement, or UUOA, to SENER for approval. The UUOA will be the governing document of the unitized consortium over the life of the Zama field, addressing such topics as initial participating interests, roles of the parties, and reimbursement of exploration and appraisal costs spent to date, as well as a redetermination mechanism for adjusting the initial participating interests as additional technical data is collected. These elements, according to Mexican regulation, should be based on standard industry practices for unitization agreements from around the world. The Zama development envisages two fixed production facilities with a total capacity for 150 thousand barrels of oil per day plus associated gas. Once installed, these platforms will be the deepest facilities ever installed in Mexico at approximately 550 feet of water.

ShowHide Related Items >><<
TALO Talos Energy
$7.95 /

-0.5 (-5.92%)

TALO Talos Energy
$7.95 /

-0.5 (-5.92%)

06/25/20 MKM Partners
Talos Energy initiated with a Buy at MKM Partners
06/24/20 MKM Partners
Talos Energy initiated with a Buy at MKM Partners
06/04/20
Fly Intel: Top five analyst initiations
06/04/20 BMO Capital
Talos Energy initiated with an Outperform at BMO Capital
TALO Talos Energy
$7.95 /

-0.5 (-5.92%)

TALO Talos Energy
$7.95 /

-0.5 (-5.92%)

Periodicals
U.S. Ambassador says Ford could close plants in U.S., Reuters says » 17:50
07/09/20
07/09
17:50
07/09/20
17:50
F

Ford

$5.85 /

-0.255 (-4.18%)

U.S. Ambassador to Mexico…

U.S. Ambassador to Mexico Christopher Landau said that Ford could have to close factories in the U.S. next week if the car maker does not receive engines produced for their vehicles in Mexico's Chihuahua state, Reuters' Anthony Esposito reports. Landau said that a senior Ford executive informed him about his company's concerns over the engines made by the car maker in Chihuahua state, where the governor has "limited industrial capacity to 50%" due to concerns about COVID-19, Esposito says. "They're saying that they're going to start shutting down factories in the United States as of next week if they don't get that rolling," added Landau, in a talk organized by the Atlantic Council. Reference Link

ShowHide Related Items >><<
F Ford
$5.85 /

-0.255 (-4.18%)

F Ford
$5.85 /

-0.255 (-4.18%)

06/25/20 Morgan Stanley
Talks with Ford dealer highlight inventory risk, says Morgan Stanley
06/24/20 Morgan Stanley
GM electric vehicle business could be worth $100B, says Morgan Stanley
06/19/20 JPMorgan
Ford price target raised to $7 from $6 at JPMorgan
06/18/20 Jefferies
Jefferies raises price targets for Ford, GM and FCA on balance sheet de-risking
F Ford
$5.85 /

-0.255 (-4.18%)

F Ford
$5.85 /

-0.255 (-4.18%)

F Ford
$5.85 /

-0.255 (-4.18%)

F Ford
$5.85 /

-0.255 (-4.18%)

Hot Stocks
Global PC market grew 11.2% y/y in Q2, says IDC » 17:46
07/09/20
07/09
17:46
07/09/20
17:46
HPQ

HP Inc.

$16.41 /

-0.35 (-2.09%)

, LNVGY

Lenovo

$0.00 /

+ (+0.00%)

, DELL

Dell Technologies

$53.73 /

-0.41 (-0.76%)

, AAPL

Apple

$382.78 /

+1.49 (+0.39%)

, MU

Micron

$49.99 /

+0.28 (+0.56%)

, WDC

Western Digital

$42.34 /

-0.45 (-1.05%)

, MSFT

Microsoft

$214.40 /

+1.51 (+0.71%)

, GOOG

Alphabet

$1,510.25 /

+14.22 (+0.95%)

, GOOGL

Alphabet Class A

$1,516.71 /

+14.12 (+0.94%)

, STX

Seagate

$46.79 /

+0.23 (+0.49%)

, QCOM

Qualcomm

$93.24 /

-0.29 (-0.31%)

, INTC

Intel

$58.43 /

-0.2 (-0.34%)

, IBM

IBM

$115.63 /

-2.09 (-1.78%)

, NTAP

NetApp

$42.29 /

-1 (-2.31%)

The second quarter of…

The second quarter of 2020 ended well for the Traditional PC market, comprised of desktops, notebooks, and workstations, with global shipments growing 11.2% year over year reaching a total of 72.3 million units, according to preliminary results from the International Data Corporation Worldwide Quarterly Personal Computing Device Tracker. As restrictions around the world tightened in the first few weeks of the quarter, demand for notebooks continued to grow to maintain continuity of business and schooling for many communities. Despite logistics issues early in the quarter, the cost and frequency of both air and sea freight inched closer to normal. This, combined with PC production ramping up, and in some cases surpassing previous levels, meant that retailers and other distributors around the world had ample supply and were ready to fulfill the surge in demand. "The strong demand driven by work-from-home as well as e-learning needs has surpassed previous expectations and has once again put the PC at the center of consumers' tech portfolio," said Jitesh Ubrani research manager for IDC's Mobile Device Trackers. "What remains to be seen is if this demand and high level of usage continues during a recession and into the post-COVID world since budgets are shrinking while schools and workplaces reopen." "Early indicators suggest strong PC shipments for education, enterprise, and consumer, muted somewhat by frozen SMBs," said Linn Huang, research vice president, Devices and Displays at IDC. "With inventory still back ordered, this goodwill will continue into July. However, as we head deeper into a global recession, the goodwill sentiment will increasingly sour." IDC noted that HP Inc. (HPQ) was the top PC company in terms of market shares at 25%, while Lenovo (LNVGY) was in second place at 24.1%, Dell (DELL) was in third at 16.6%, and Apple (AAPL) was fourth at 7.7%. Other companies in the PC space include Micron (MU), Western Digital (WDC), Microsoft (MSFT), Alphabet (GOOG), Seagate (STX), Qualcomm (QCOM), Intel (INTC), IBM (IBM), and NetApp (NTAP).

ShowHide Related Items >><<
WDC Western Digital
$42.34 /

-0.45 (-1.05%)

STX Seagate
$46.79 /

+0.23 (+0.49%)

QCOM Qualcomm
$93.24 /

-0.29 (-0.31%)

NTAP NetApp
$42.29 /

-1 (-2.31%)

MU Micron
$49.99 /

+0.28 (+0.56%)

MSFT Microsoft
$214.40 /

+1.51 (+0.71%)

LNVGY Lenovo
$0.00 /

+ (+0.00%)

INTC Intel
$58.43 /

-0.2 (-0.34%)

IBM IBM
$115.63 /

-2.09 (-1.78%)

HPQ HP Inc.
$16.41 /

-0.35 (-2.09%)

GOOG Alphabet
$1,510.25 /

+14.22 (+0.95%)

DELL Dell Technologies
$53.73 /

-0.41 (-0.76%)

AAPL Apple
$382.78 /

+1.49 (+0.39%)

HPQ HP Inc.
$16.41 /

-0.35 (-2.09%)

06/30/20 Cowen
HP Inc. initiated with a Market Perform at Cowen
05/28/20
Fly Intel: Top five analyst downgrades
05/28/20 JPMorgan
HP Inc. downgraded to Neutral from Overweight at JPMorgan
05/26/20 Credit Suisse
HP Inc. price target lowered to $17 from $22 at Credit Suisse
LNVGY Lenovo
$0.00 /

+ (+0.00%)

05/21/20 JPMorgan
Lenovo downgraded to Neutral from Overweight at JPMorgan
03/27/20 Goldman Sachs
Lenovo downgraded to Neutral from Buy at Goldman Sachs
DELL Dell Technologies
$53.73 /

-0.41 (-0.76%)

07/09/20
Fly Intel: Top five analyst initiations
07/09/20 Daiwa
Dell Technologies initiated with a Neutral at Daiwa
07/07/20 Deutsche Bank
Dell offers 20%-30% upside on standalone basis, says Deutsche Bank
06/30/20 Cowen
Dell Technologies initiated with a Market Perform at Cowen
AAPL Apple
$382.78 /

+1.49 (+0.39%)

07/09/20 Nomura Instinet
Nomura says Apple iPhone shipments in China pressured by 5G models in June
07/08/20 Deutsche Bank
'Nervous' Deutsche Bank raises Apple price target to $400 from $380
07/07/20 Raymond James
Apple price target raised to $400 from $340 at Raymond James
07/06/20 Loop Capital
Apple's build plan update negates speculation of cut, says Loop Capital
MU Micron
$49.99 /

+0.28 (+0.56%)

06/30/20 RBC Capital
Micron price target raised to $60 from $55 at RBC Capital
06/30/20 Morgan Stanley
Morgan Stanley would add to Micron positions on weakness in coming 'rough patch'
06/30/20 Raymond James
Micron price target raised to $65 from $60 at Raymond James
06/30/20 Mizuho
Micron price target raised to $63 from $60 at Mizuho
WDC Western Digital
$42.34 /

-0.45 (-1.05%)

06/30/20 Benchmark
Micron report and guidance 'bode well' for Western Digital, says Benchmark
06/26/20 KeyBanc
Memory supply remains limited in 2H amid low visibility, says KeyBanc
06/22/20 Benchmark
Western Digital upgraded to Buy from Hold at Benchmark
06/19/20 Benchmark
Benchmark says Samsung's NAND chip issues likely positive for HDD makers
MSFT Microsoft
$214.40 /

+1.51 (+0.71%)

07/09/20 Morgan Stanley
Microsoft price target raised to $230 from $198 at Morgan Stanley
07/09/20 Wedbush
Microsoft price target raised to $260 from $220 at Wedbush
07/07/20 Loop Capital
Logitech price target raised to $78 from $58 at Loop Capital
07/06/20 Morgan Stanley
Microsoft skilling focus tempers some Pluralsight optimism, says Morgan Stanley
GOOG Alphabet
$1,510.25 /

+14.22 (+0.95%)

07/09/20 Wedbush
Pinterest price target raised to $31 from $26 at Wedbush
07/07/20 BofA
Potential U.S. ban of TikTok could be tailwind to Snap engagement, says BofA
06/29/20 Stifel
Stifel says Facebook sales won't be materially hurt unless ad boycott broadens
06/25/20 Baird
Alphabet price target raised to $1,650 from $1,500 at Baird
GOOGL Alphabet Class A
$1,516.71 /

+14.12 (+0.94%)

STX Seagate
$46.79 /

+0.23 (+0.49%)

06/08/20 Rosenblatt
Rosenblatt starts Western Digital at Neutral, sees technology lagging Seagate
06/08/20 Rosenblatt
Rosenblatt starts Seagate at Buy, sees technology lead over Western Digital
06/08/20 Rosenblatt
Seagate initiated with a Buy at Rosenblatt
QCOM Qualcomm
$93.24 /

-0.29 (-0.31%)

07/01/20 BofA
BofA makes 14 additions, four deletions from US 1 list
06/16/20
Fly Intel: Top five analyst upgrades
06/16/20 Morgan Stanley
Qualcomm upgraded to Overweight on improving smartphone demand at Morgan Stanley
06/16/20 Morgan Stanley
Qualcomm upgraded to Overweight from Equal Weight at Morgan Stanley
INTC Intel
$58.43 /

-0.2 (-0.34%)

07/07/20 William Blair
William Blair says trends helping MaxLinear likely boosting unit being bought
07/06/20
Fly Intel: Top five analyst downgrades
07/06/20 Goldman Sachs
Intel downgraded to Sell from Neutral at Goldman Sachs
IBM IBM
$115.63 /

-2.09 (-1.78%)

07/08/20 Stifel
IBM consensus for second half, 2021 appears 'reasonable,' says Stifel
06/09/20 DA Davidson
DA Davidson says Cloudera sale 'increasingly likely,' IBM seen as possible buyer
04/21/20 Morgan Stanley
Krishna years away from returning IBM to sustainable growth, says Morgan Stanley
04/21/20 Wedbush
IBM price target lowered to $140 from $155 at Wedbush
NTAP NetApp
$42.29 /

-1 (-2.31%)

06/26/20
Fly Intel: Top five analyst upgrades
06/26/20 BofA
NetApp upgraded to Buy from Neutral at BofA
06/26/20 BofA
NetApp upgraded to Buy from Neutral at BofA
06/18/20 Deutsche Bank
NetApp initiated with a Hold at Deutsche Bank
WDC Western Digital
$42.34 /

-0.45 (-1.05%)

STX Seagate
$46.79 /

+0.23 (+0.49%)

QCOM Qualcomm
$93.24 /

-0.29 (-0.31%)

NTAP NetApp
$42.29 /

-1 (-2.31%)

MU Micron
$49.99 /

+0.28 (+0.56%)

MSFT Microsoft
$214.40 /

+1.51 (+0.71%)

INTC Intel
$58.43 /

-0.2 (-0.34%)

IBM IBM
$115.63 /

-2.09 (-1.78%)

HPQ HP Inc.
$16.41 /

-0.35 (-2.09%)

GOOG Alphabet
$1,510.25 /

+14.22 (+0.95%)

DELL Dell Technologies
$53.73 /

-0.41 (-0.76%)

AAPL Apple
$382.78 /

+1.49 (+0.39%)

WDC Western Digital
$42.34 /

-0.45 (-1.05%)

STX Seagate
$46.79 /

+0.23 (+0.49%)

QCOM Qualcomm
$93.24 /

-0.29 (-0.31%)

MU Micron
$49.99 /

+0.28 (+0.56%)

MSFT Microsoft
$214.40 /

+1.51 (+0.71%)

LNVGY Lenovo
$0.00 /

+ (+0.00%)

INTC Intel
$58.43 /

-0.2 (-0.34%)

IBM IBM
$115.63 /

-2.09 (-1.78%)

HPQ HP Inc.
$16.41 /

-0.35 (-2.09%)

GOOG Alphabet
$1,510.25 /

+14.22 (+0.95%)

DELL Dell Technologies
$53.73 /

-0.41 (-0.76%)

AAPL Apple
$382.78 /

+1.49 (+0.39%)

WDC Western Digital
$42.34 /

-0.45 (-1.05%)

STX Seagate
$46.79 /

+0.23 (+0.49%)

QCOM Qualcomm
$93.24 /

-0.29 (-0.31%)

NTAP NetApp
$42.29 /

-1 (-2.31%)

MU Micron
$49.99 /

+0.28 (+0.56%)

MSFT Microsoft
$214.40 /

+1.51 (+0.71%)

INTC Intel
$58.43 /

-0.2 (-0.34%)

IBM IBM
$115.63 /

-2.09 (-1.78%)

HPQ HP Inc.
$16.41 /

-0.35 (-2.09%)

GOOG Alphabet
$1,510.25 /

+14.22 (+0.95%)

DELL Dell Technologies
$53.73 /

-0.41 (-0.76%)

AAPL Apple
$382.78 /

+1.49 (+0.39%)

WDC Western Digital
$42.34 /

-0.45 (-1.05%)

STX Seagate
$46.79 /

+0.23 (+0.49%)

QCOM Qualcomm
$93.24 /

-0.29 (-0.31%)

NTAP NetApp
$42.29 /

-1 (-2.31%)

MU Micron
$49.99 /

+0.28 (+0.56%)

MSFT Microsoft
$214.40 /

+1.51 (+0.71%)

INTC Intel
$58.43 /

-0.2 (-0.34%)

IBM IBM
$115.63 /

-2.09 (-1.78%)

HPQ HP Inc.
$16.41 /

-0.35 (-2.09%)

GOOGL Alphabet Class A
$1,516.71 /

+14.12 (+0.94%)

GOOG Alphabet
$1,510.25 /

+14.22 (+0.95%)

DELL Dell Technologies
$53.73 /

-0.41 (-0.76%)

AAPL Apple
$382.78 /

+1.49 (+0.39%)

INTC Intel
$58.43 /

-0.2 (-0.34%)

GOOG Alphabet
$1,510.25 /

+14.22 (+0.95%)

AAPL Apple
$382.78 /

+1.49 (+0.39%)

Hot Stocks
Acreage gets provisional OK to sell adult-use cannabis at 2 Massachusetts sites » 17:43
07/09/20
07/09
17:43
07/09/20
17:43
ACRGF

Acreage Holdings

$0.00 /

+ (+0.00%)

, MJ

ETFMG Alternative Harvest ETF

$12.77 /

-0.26 (-2.00%)

Acreage Holdings…

Acreage Holdings announced that the Massachusetts Cannabis Control Commission has granted the company provisional licenses for the retail sale of adult-use cannabis in Worcester and Shrewsbury. Acreage will add adult-use retail sales to its existing The Botanist dispensary in Worcester, MA, which opened as a medical marijuana treatment center in 2018, and it will open a new The Botanist dispensary in Shrewsbury, MA. The CCC voted to grant the provisional licenses at its monthly meeting earlier on June 9. Acreage anticipates beginning retail sales at both locations as quickly as possible following further regulatory inspections and approvals. The Worcester dispensary is located at 65 Pullman Street, Worcester, MA. The Shrewsbury dispensary will be located at 235 Hartford Turnpike, Shrewsbury, MA. The company's third The Botanist dispensary in Massachusetts is located in the Town of Leominster. Once all approvals are completed and the dispensaries are fully operational, Acreage anticipates adding more than 40 new jobs in Massachusetts. Separately at the CCC meeting, the commissioners approved a stipulated agreement in which Acreage has agreed to make a $250,000 payment to the Cannabis Control Commission Regulation Fund. The payment is related to previously terminated Management Services Agreements. With Thursday's actions, Acreage looks forward to completing the licensing process and bringing the Commonwealth's citizens its full House of Brands product portfolio, including its The Botanist, Live Resin and Tweed brands, the latter being a Canopy Growth brand that Acreage introduced in the U.S. last year.

ShowHide Related Items >><<
ACRGF Acreage Holdings
$0.00 /

+ (+0.00%)

ACRGF Acreage Holdings
$0.00 /

+ (+0.00%)

02/14/20 Cantor Fitzgerald
Cantor initiates 10 cannabis names, sees opportunity after sellofff
02/13/20 Cantor Fitzgerald
Acreage Holdings initiated with a Neutral at Cantor Fitzgerald
10/31/19 Ladenburg
Cannabis sector investor sentiment is now 'very low,' says Ladenburg
09/20/19 MKM Partners
MKM starts Acreage at Buy on 'extreme disconnect' from Canopy offer
MJ ETFMG Alternative Harvest ETF
$12.77 /

-0.26 (-2.00%)

ACRGF Acreage Holdings
$0.00 /

+ (+0.00%)

MJ ETFMG Alternative Harvest ETF
$12.77 /

-0.26 (-2.00%)

Hot Stocks
Ipsen receives FDA approval for expanded use of Dysport in pediatric patients » 17:43
07/09/20
07/09
17:43
07/09/20
17:43
IPSEY

Ipsen

$0.00 /

+ (+0.00%)

Ipsen Biopharmaceuticals,…

Ipsen Biopharmaceuticals, an affiliate of Ipsen, announced that the FDA has approved the expanded use of Dysport in pediatric patients. When Dysport was first FDA-approved in 2016 for pediatric lower limb spasticity, Ipsen was granted orphan drug exclusivity for pediatric patients whose lower limb spasticity was caused by cerebral palsy, or CP.1 Similarly, in 2019, Dysport received FDA approval for the treatment of upper limb spasticity in children two years of age and older, excluding upper limb spasticity caused by CP, due to orphan drug exclusivity granted to another manufacturer. Ipsen has worked with the FDA and this manufacturer to selectively waive their respective exclusivities to better support patient care. As a result, Dysport is now FDA-approved to treat both upper and lower limb spasticity in pediatric patients two years of age and older, including spasticity caused by cerebral palsy.

ShowHide Related Items >><<
IPSEY Ipsen
$0.00 /

+ (+0.00%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

06/08/20 Bryan Garnier
Ipsen upgraded to Buy from Neutral at Bryan Garnier
06/01/20 Barclays
Ipsen price target raised to EUR 72 from EUR 62 at Barclays
06/01/20 BofA
Ipsen upgraded to Buy from Neutral at BofA
05/18/20 JPMorgan
Ipsen upgraded to Neutral on Cabometyx potential at JPMorgan
IPSEY Ipsen
$0.00 /

+ (+0.00%)

Syndicate
Akerna files to sell 3.29M shares of common stock for holders  17:33
07/09/20
07/09
17:33
07/09/20
17:33
KERN

Akerna

$7.25 /

-0.21 (-2.82%)

 
ShowHide Related Items >><<
KERN Akerna
$7.25 /

-0.21 (-2.82%)

KERN Akerna
$7.25 /

-0.21 (-2.82%)

KERN Akerna
$7.25 /

-0.21 (-2.82%)

KERN Akerna
$7.25 /

-0.21 (-2.82%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.